TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• TuHURA Biosciences, Inc. (NASDAQ:HURA) has received a consensus rating of "Buy" from five ratings firms, with three analysts rating it as a buy and two as a strong buy.
• The average 1-year target price for TuHURA shares is approximately $12.67, despite the company's recent earnings report showing a loss of ($0.21) per share.
• Significant investments from hedge funds have been noted, with firms like Millennium Management and Bank of America purchasing new positions, highlighting growing institutional interest in TuHURA.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has been given an average recommendation of "Buy" by the five ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.6667.

A number of brokerages recently commented on HURA. Brookline Capital Management upgraded shares of TuHURA Biosciences to a "strong-buy" rating in a research report on Monday, June 23rd. Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th.

TuHURA Biosciences Stock Performance

TuHURA Biosciences stock opened at $2.54 on Thursday. The firm's fifty day moving average price is $2.67 and its 200-day moving average price is $3.04. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $8.40.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

Hedge Funds Weigh In On TuHURA Biosciences

A number of large investors have recently added to or reduced their stakes in HURA. Bank of America Corp DE purchased a new position in TuHURA Biosciences in the 4th quarter worth $59,000. Millennium Management LLC bought a new stake in TuHURA Biosciences in the 4th quarter worth $138,000. Squarepoint Ops LLC bought a new stake in TuHURA Biosciences in the 4th quarter worth $223,000. Sabal Trust CO bought a new stake in TuHURA Biosciences in the 1st quarter worth $127,000. Finally, Apollon Wealth Management LLC grew its holdings in TuHURA Biosciences by 86.0% in the 1st quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock worth $371,000 after acquiring an additional 53,154 shares during the last quarter. Hedge funds and other institutional investors own 0.62% of the company's stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.